达安基因(002030) - 2018 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2018 was CNY 388.69 million, representing an increase of 11.11% compared to CNY 349.82 million in the same period last year[8]. - Net profit attributable to shareholders was CNY 27.80 million, a 3.03% increase from CNY 26.98 million year-on-year[8]. - The net profit after deducting non-recurring gains and losses was CNY 24.49 million, showing a significant increase of 36.87% from CNY 17.89 million in the previous year[8]. - The net profit attributable to shareholders for the first half of 2018 is expected to range from RMB 52.29 million to RMB 69.73 million, representing a decrease of 10.00% to an increase of 20.00% compared to RMB 58.11 million in the same period of 2017[29]. Cash Flow and Assets - The net cash flow from operating activities improved to -CNY 127.53 million, a 19.09% improvement from -CNY 157.62 million in the same period last year[8]. - Total assets at the end of the reporting period were CNY 4.79 billion, up 3.23% from CNY 4.64 billion at the end of the previous year[8]. - Net assets attributable to shareholders increased to CNY 1.74 billion, reflecting a growth of 3.68% from CNY 1.68 billion at the end of the previous year[8]. - The company reported a 55.56% improvement in cash flow from investment activities, with cash outflow decreasing from -RMB 76,355,107.12 to -RMB 33,933,399.58[24]. Shareholder Information - The company reported a total of 95,488 common shareholders at the end of the reporting period[14]. - The top shareholder, Guangzhou Zhongda Holdings Co., Ltd., held 16.63% of the shares, amounting to 120,553,716 shares[14]. Government and Other Income - Government subsidies recognized in the current period amounted to CNY 6.41 million, primarily related to various government grants[11]. - The company’s other income decreased by 49.21% to RMB 5,756,182.85, due to delays in the allocation of research and development subsidies compared to the previous year[22]. Investments and Financing - The company's investment income decreased by 100.24% to -RMB 3,116.13, compared to RMB 1,316,263.63 in the same period last year, due to reduced investment income from joint ventures[22]. - Cash generated from financing activities increased by 7,098.79% to RMB 191,218,959.28, compared to -RMB 2,732,172.10 in the same period last year, due to an increase in cash received from borrowings[24]. - The company plans to raise up to RMB 150 million through a non-public offering of 46,324,891 shares at a price of RMB 32.38 per share, aimed at expanding its fluorescence PCR product line and constructing a research center[25]. Liabilities and Employee Compensation - The company’s long-term borrowings due within one year increased by 146.40% to RMB 163,257,172.93, indicating a rise in short-term financial obligations[20]. - The company’s employee compensation payable decreased by 55.79% to RMB 18,583,427.73, as year-end bonuses were paid out in the first quarter[20]. Intangible Assets and Receivables - The company's intangible assets increased by 101.19% to RMB 170,427,027.35, attributed to the investment in land by minority shareholders of the subsidiary[20]. - Other receivables increased by 48.77% to RMB 70,445,830.88, indicating an increase in receivables from transactions[20]. Return on Equity - The weighted average return on equity was 1.60%, slightly down from 1.67% in the previous year[8].